Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy

Biomaterials

Volumn 30, Issue 35, 2009, Pages 6757-6767

  Hori, Yuki ^a,b   Stern, Patrick J ^b   Hynes, Richard O ^b,c   Irvine, Darrell J ^a,b,c  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Alginate; Cancer vaccines; Dendritic cells; Hydrogels; IL 15 superagonist; Local tumor immunotherapy

Indexed keywords

ALGINATE GEL; ANTI-TUMOR ACTIVITIES; CANCER IMMUNOTHERAPY; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; EXTRACELLULAR MATRICES; IL-15 SUPERAGONIST; IMMUNE CELLS; IMMUNE RESPONSE; LOCAL RECURRENCE; LOCAL THERAPY; LOCAL TUMOR IMMUNOTHERAPY; MATRIX; MATRIX INFILTRATION; MELANOMA TUMORS; SOLID TUMORS; TOLL-LIKE RECEPTORS; TUMOR GROWTH; TUMOR IMMUNOTHERAPY; TUMOR SITE;

ALGINATE; ANIMALS; CELL MEMBRANES; DENDRIMERS; DERMATOLOGY; GELATION; GELS; HYDROGELS; IMMUNOLOGY; ONCOLOGY; POLYSACCHARIDES; SEEPAGE; SIMULATED ANNEALING; SOIL MECHANICS; VACCINES;

TUMORS;

ALGINIC ACID; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 15 SUPERAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EXTRACELLULAR MATRIX; GEL; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; SYSTEMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ALGINATES; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; EXTRACELLULAR MATRIX; HYDROGELS; IMMUNOTHERAPY; INTERLEUKIN-15; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASMS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA; MURINAE;

EID: 70349854888     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.08.037     Document Type: Article

References (47)

1. Gimbel M.I., Delman K.A., and Zager J.S. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 15 3 (2008) 225-232
2. Crittenden M.R., Thanarajasingam U., Vile R.G., and Gough M.J. Intratumoral immunotherapy: using the tumour against itself. Immunology 114 1 (2005) 11-22
3. Joosten J., Jager G., Oyen W., Wobbes T., and Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 31 10 (2005) 1152-1159
4. Herber D.L., Nagaraj S., Djeu J.Y., and Gabrilovich D.I. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 67 11 (2007) 5067-5069
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 4 (2005) 263-274
6. Jackaman C., Lew A.M., Zhan Y., Allan J.E., Koloska B., Graham P.T., et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20 11 (2008) 1467-1479
7. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13 (1995) 399-415
8. Furumoto K., Soares L., Engleman E.G., and Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113 5 (2004) 774-783
9. Li J., Song W., Czerwinski D.K., Varghese B., Uematsu S., Akira S., et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 179 4 (2007) 2493-2500
10. Nierkens S., den Brok M.H., Sutmuller R.P., Grauer O.M., Bennink E., Morgan M.E., et al. In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res 68 13 (2008) 5390-5396
11. Broomfield S.A., van der Most R.G., Prosser A.C., Mahendran S., Tovey M.G., Smyth M.J., et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 182 9 (2009) 5217-5224
12. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10 2 (2004) 187-192
13. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25 7 (2007) 876-883
14. Hanes J., Sills A., Zhao Z., Suh K.W., Tyler B., DiMeco F., et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18 7 (2001) 899-906
15. Bos G.W., Jacobs J.J., Koten J.W., Van Tomme S., Veldhuis T., van Nostrum C.F., et al. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Eur J Pharm Sci 21 4 (2004) 561-567
16. Egilmez N.K., Jong Y.S., Sabel M.S., Jacob J.S., Mathiowitz E., and Bankert R.B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 60 14 (2000) 3832-3837
17. Hori Y., Winans A.M., Huang C.C., Horrigan E.M., and Irvine D.J. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 29 27 (2008) 3671-3682
18. Hori Y., Winans A.M., and Irvine D.J. Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomater 5 4 (2009) 969-982
19. Soon-Shiong P., Heintz R.E., Merideth N., Yao Q.X., Yao Z., Zheng T., et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343 8903 (1994) 950-951
20. Sellke F.W., Laham R.J., Edelman E.R., Pearlman J.D., and Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 65 6 (1998) 1540-1544
21. Hasse C., Klock G., Schlosser A., Zimmermann U., and Rothmund M. Parathyroid allotransplantation without immunosuppression. Lancet 350 9087 (1997) 1296-1297
22. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 6 (1992) 1693-1702
23. Stachowiak A.N., Wang Y., Huang Y.C., and Irvine D.J. Homeostatic lymphoid chemokines synergize with adhesion ligands to trigger T and B lymphocyte chemokinesis. J Immunol 177 4 (2006) 2340-2348
24. Jotwani R., Pulendran B., Agrawal S., and Cutler C.W. Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol 33 11 (2003) 2980-2986
25. Epardaud M., Elpek K.G., Rubinstein M.P., Yonekura A.R., Bellemare-Pelletier A., Bronson R., et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68 8 (2008) 2972-2983
26. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12 3 (2006) 335-341
27. Dubois S., Patel H.J., Zhang M., Waldmann T.A., and Muller J.R. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 180 4 (2008) 2099-2106
28. Rubinstein M.P., Kovar M., Purton J.F., Cho J.H., Boyman O., Surh C.D., et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 103 24 (2006) 9166-9171
29. Stoklasek T.A., Schluns K.S., and Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177 9 (2006) 6072-6080
30. Silva E.A., and Mooney D.J. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5 3 (2007) 590-598
31. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., and Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65 8 (2005) 3437-3446
32. den Brok M.H., Sutmuller R.P., Nierkens S., Bennink E.J., Toonen L.W., Figdor C.G., et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 66 14 (2006) 7285-7292
33. Quezada S.A., Peggs K.S., Curran M.A., and Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116 7 (2006) 1935-1945
34. Quezada S.A., Peggs K.S., Simpson T.R., Shen Y., Littman D.R., and Allison J.P. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 205 9 (2008) 2125-2138
35. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175 9 (2005) 6169-6176
36. Ryschich E., Schmidt J., Hammerling G.J., Klar E., and Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer 97 6 (2002) 719-725
37. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 95 3 (1998) 1178-1183
38. Wang H.Y., and Wang R.F. Regulatory T cells and cancer. Curr Opin Immunol 19 2 (2007) 217-223
39. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13 18 Pt 1 (2007) 5243-5248
40. Ali O.A., Huebsch N., Cao L., Dranoff G., and Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8 2 (2009) 151-158
41. Heit A., Schmitz F., Haas T., Busch D.H., and Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 37 8 (2007) 2063-2074
42. Augst A.D., Kong H.J., and Mooney D.J. Alginate hydrogels as biomaterials. Macromol Biosci 6 8 (2006) 623-633
43. Gilboa E. DC-based cancer vaccines. J Clin Invest 117 5 (2007) 1195-1203
44. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 29 3 (2008) 372-383
45. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 7161 (2007) 419-426
46. Mohamadzadeh M., Berard F., Essert G., Chalouni C., Pulendran B., Davoust J., et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 194 7 (2001) 1013-1020
47. Ohteki T., Suzue K., Maki C., Ota T., and Koyasu S. Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Immunol 2 12 (2001) 1138-1143